Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Geopolitics: Understanding the shifts behind the headlines
Exploring how geopolitical dynamics are evolving, what they may mean for markets and how wealth portfolios can be positioned through periods of height
Pensions dashboards are schemes ready for the next step
TPR dashboards lead Lucy Stone emphasises that connection is just the start of the dashboards journey, urging schemes to keep up the momentum, focus o
Reflections on 20 years of Pension Risk Transfer
Buy-ins are now well-established and regularly dominate the headlines in the pensions press. But that has not always been the case. In this article, I

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.